Efficacy and Safety of Tofacitinib in Patients With COVID-19 Pneumonia

NCT04750317 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

414

Enrollment

OTHER

Sponsor class

Conditions

COVID-19

Interventions

DRUG: Tofacitinib

Sponsor

I.M. Sechenov First Moscow State Medical University